TCG raises over $400M for single-asset biologics approach with 10th fund, R&D lab

As the biotech industry grapples with how to fund drug development in a world of increasing research costs, rising drug prices and government-related risk, a legacy investor is taking a different approach for its 10th fund.

The Column Group told Endpoints News exclusively on Thursday that it has raised over…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks